Rhumbline Advisers Has $29.11 Million Stake in HealthEquity, Inc. $HQY

Rhumbline Advisers boosted its position in HealthEquity, Inc. (NASDAQ:HQY) by 2.9% during the second quarter, Holdings Channel reports. The institutional investor owned 277,915 shares of the company’s stock after purchasing an additional 7,938 shares during the quarter. Rhumbline Advisers’ holdings in HealthEquity were worth $29,114,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in shares of HealthEquity by 995.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company’s stock valued at $56,500,000 after acquiring an additional 580,988 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of HealthEquity by 124.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,265,208 shares of the company’s stock valued at $132,543,000 after acquiring an additional 701,819 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in shares of HealthEquity during the second quarter worth approximately $492,000. Ashford Capital Management Inc. raised its holdings in HealthEquity by 2.1% in the 1st quarter. Ashford Capital Management Inc. now owns 274,999 shares of the company’s stock valued at $24,302,000 after acquiring an additional 5,687 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in HealthEquity by 44.8% during the second quarter. Artisan Partners Limited Partnership now owns 621,647 shares of the company’s stock worth $65,124,000 after buying an additional 192,252 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Stock Down 0.4%

Shares of NASDAQ HQY opened at $104.99 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23. The stock has a market capitalization of $9.05 billion, a PE ratio of 63.63, a P/E/G ratio of 1.36 and a beta of 0.47. HealthEquity, Inc. has a one year low of $74.07 and a one year high of $116.65. The business’s fifty day moving average price is $95.70 and its 200-day moving average price is $96.73.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 2nd. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $325.80 million for the quarter, compared to analysts’ expectations of $320.68 million. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, equities research analysts anticipate that HealthEquity, Inc. will post 2.32 EPS for the current year.

Analyst Upgrades and Downgrades

HQY has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on shares of HealthEquity from $125.00 to $126.00 and gave the company an “overweight” rating in a research report on Wednesday, September 3rd. Jefferies Financial Group increased their price target on HealthEquity from $130.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, September 3rd. KeyCorp cut their target price on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. BMO Capital Markets assumed coverage on HealthEquity in a research report on Thursday, November 13th. They set a “market perform” rating and a $100.00 target price on the stock. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of HealthEquity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, HealthEquity currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Insider Activity at HealthEquity

In related news, EVP Delano Ladd sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $104.56, for a total value of $156,840.00. Following the completion of the transaction, the executive vice president directly owned 75,479 shares of the company’s stock, valued at approximately $7,892,084.24. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Henry Fiore sold 1,781 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total transaction of $157,102.01. Following the sale, the executive vice president directly owned 49,795 shares in the company, valued at $4,392,416.95. The trade was a 3.45% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 10,781 shares of company stock worth $1,016,707. Insiders own 1.50% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.